MARKETS / NASDAQ / MDXH
NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP

Mdxhealth SA MDXH

7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$107.9M
▲ 19.8% vs FY2024
EPS · FY25
$-0.67
Dividend / sh · FY25
Payout · FY25
ROE · FY25
Net margin · FY25
-31.1%
Dividend coverage
-3.3×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 107.9M
Revenue, FY2025 · full 7-year series below
Revenue Net income
0.040.080.120.1-0.0201920222025
0.040.080.120.1-0.0201920222025

The company lost 31 cents on every revenue dollar this year.

Per share
USD -0.67
Diluted EPS, FY2025
EPS Dividend
0.40.81.2-0.67201920222025
0.40.81.2-0.67201920222025

The dividend was paid in a year without profit.

Profitability
Return on equity, FY2025
ROE
0.250.50.751201920222025
0.250.50.751201920222025
Operating margin-13.4%
Net margin-31.1%
Return on assets-22.0%

Returned to shareholders
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+42.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+42.8%
+42.3%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
Shares outstanding, FY2025
Change, 5 years
Change, 10 years

A share split breaks the comparison across the period, so we leave it out.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 148.0M
total assets, end of FY2025
Total assetsUSD 148.0M
CashUSD 29.0M
Current ratio1.08×

History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.1
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
−0.0
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.67
−1.16
−1.66
−2.78
−2.38
−0.34
−0.69
Dividend / sh $
·
·
·
0.85
0.85
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
25 of 26
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 1 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed